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in Humans
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Stimulation of human vaccinia virus immune peripheral blood mononuclear cells in vitro from vaccinia
virus-immune donors with live vaccinia virus-infected autologous cells generated vaccinia virus-specific
cytotoxic T lymphocytes (CTL) capable of lysing vaccinia virus-infected cells. We generated vaccinia
virus-specific CD8+ clones and CD4+ CTL lines by limiting dilution from two donors by using peripheral blood
mononuclear cells obtained 2 months or 4 years postrevaccination with vaccinia virus. These results
demonstrate that vaccinia virus-specific CTL are generated as a result of immunization of humans with
vaccinia virus and that both CD8+- and CD4+-specific T cells are maintained as memory cells.
Successful immunization can be defined as induction of
immunologic memory specific for defense against microor-
ganisms that can be evoked to protect a host against chal-
lenge. Sufficient immunologic memory must be generated to
provide long-lasting protection. Such long-lived immunity is
possible and has been achieved with smallpox vaccines.
Vaccination of humans with vaccinia virus represents the
first example of worldwide eradication of a major human
disease (9).
Within the last decade, a new and exciting approach to
vaccine development has evolved that is based on introduc-
tion of genes that encode microbial antigens into a relatively
nonpathogenic virus, such as vaccinia virus, and infection of
individuals with the recombinant virus to generate immune
responses against the foreign protein. Vaccinia virus has
been used as a potential viral vector vaccine because of its
broad host range, its prior use as the vaccine to eradicate
smallpox in humans, and its utility in expression of a variety
of foreign antigens which can immunize animals successfully
(1, 20, 27). Although vaccinia virus recombinants are being
considered as vaccines against diseases of major medical
importance, very little is known about human T-cell re-
sponses to vaccinia virus.
The importance of the cellular immune response during
vaccinia virus infection was demonstrated in 1960 by
Kempe, who reported that children with agammaglobuline-
mia had no adverse reactions to immunization with live
vaccinia virus (13). Other clinical studies showed that indi-
viduals with deficient T-lymphocyte responses were more
likely to have disseminated infections following immuniza-
tion with vaccinia virus (10, 21). Helper and cytotoxic T-cell
responses following infection with poxviruses have been
documented in a number of different animal species (2, 5,
12); however, the presence of CD4+ and CD8+ cytotoxic T
lymphocytes (CTL) in vaccinia virus-immunized humans
had not been demonstrated. Investigators at several labora-
tories have previously attempted to detect vaccinia virus-
specific CTL responses in humans postimmunization but
have reported negative results (11, 22, 26). Littaua et al.,
however, recently demonstrated that vaccinia virus-specific
memory CD4+ CTL are present in vivo and could be cloned
* Corresponding author.
from peripheral blood mononuclear cells (PBMC) taken from
an immune individual (15). It still remained unclear whether
CD8+ CTL, which recognize viral antigens in association
with class I major histocompatibility complex (MHC) mole-
cules, are generated in humans vaccinated with vaccinia
virus.
In this report, we describe the proliferation of human
immune PBMC in response to vaccinia virus-infected cells
and demonstrate that vaccinia virus-specific memory CD8+
CTL exist in human immune PBMC. In addition, we gener-
ated vaccinia virus-specific CD8+ CTL clones and lines from
two individuals. The results reported in this communication
establish the existence of vaccinia virus-specific CD8+ CTL
in humans and provide useful information concerning the
potential use of recombinant vaccinia viruses as vaccines in
humans.
MATERIALS AND METHODS
Human PBMC. Blood was obtained from three healthy
donors who had received the standard New York City Board
of Health (NYCBH) strain of vaccinia virus as a smallpox
vaccine (Dryvax; Wyeth Laboratories, Philadelphia, Pa.) 2
months or 4 years earlier. PBMC were separated by the
Ficoll-Hypaque density gradient centrifugation method.
Cells were resuspended in RPMI 1640 medium containing
15% fetal bovine serum (FBS; GIBCO Laboratories, Grand
Island, N.Y.) and 10% dimethyl sulfoxide (Fisher Scientific
Co., Pittsburgh, Pa.) and cryopreserved until use.
Cell lines. Skin fibroblast cultures were established by
using a 3-mm-diameter biopsy sample of skin. The sample
was minced, cells were passed several times in 75-cm2 flasks
before being harvested, and aliquots were cryopreserved in
liquid nitrogen for subsequent use as target cells in CTL
assays. These cells were maintained in minimal essential
medium with 10% FBS.
B-lymphoblastoid cell lines (B-LCL) were established
from healthy, vaccinia virus-immune donors by infecting
PBMC with Epstein-Barr virus obtained from an infected
marmoset cell line, B95-8 (25), obtained from the American
Type Culture Collection. B-LCL were maintained in RPMI
1640 containing 10% heat-inactivated FBS. In addition, we
used HLA-typed allogeneic B-LCL, described below under
HLA typing, in the HLA restriction experiments.
1538
 at UNIV O
F M
ASS M
ED SCH on August 4, 2008 
jvi.asm.org
D
ow
nloaded from
 
VACCINIA VIRUS-SPECIFIC HUMAN CD8+ CTL 1539
Stimulation ofPBMC with live virus. The NYCBH strain of
vaccinia virus was used in all experiments, and two methods
of virus stimulation were employed. To stimulate cultures
with live vaccinia virus, virus was added directly to the
culture medium at the desired multiplicity of infection
(MOI). Stimulation with vaccinia virus-infected autologous
PBMC was carried out by infecting aliquots (10%) of total
PBMC with virus at the desired MOI in less than 0.5 ml of
RPMI 1640 for 2 h at 37°C. The infected cells were then
washed and resuspended in 10% heat-inactivated FBS-10%
T-cell growth factor (Cellular Products, Inc., Buffalo,
N.Y.)-10% heat-inactivated human AB serum (Hazleton
Research Products, Inc., Lenexa, Kans.) in RPMI 1640. In
some experiments, the 10% human AB serum was replaced
with 10% heat-inactivated human immune sera obtained
from donors 2 to 4 months post revaccination. These sera
contained high concentrations of anti-vaccinia virus antibod-
ies, as determined by Western blotting (immunoblotting) and
by plaque neutralization assays (data not shown). The stim-
ulator cells were mixed with the remaining 90% responder
PBMC (for establishment of bulk cultures) or with gamma-
irradiated (3,000 R) autologous PBMC (for subsequent stim-
ulation of cells in bulk cultures) at 106 total cells per ml
before addition to the culture.
Proliferation assays. Proliferation assays were performed
in 96-well round-bottom plates by addition of 2 x 105
immune donor PBMC in RPMI 1640-10% human AB serum
to triplicate wells in the presence of vaccinia virus antigen
for 4 days at 37°C. We then added 1.25 ,uCi (46 kBq) of[3H]thymidine (Dupont, NEN Research Products, Boston,
Mass.) to each well and further incubated the plates for 16 to
18 h. The cells were then harvested by using a Titertek
Multiharvester (Skatron, Inc., Sterling, Va.), and [3H]thy-
midine was counted in a liquid scintillation counter (Packard
Instrument Co., Inc., Rockville, Md.).
Cell surface antigen analysis. Anti-Leu4 (CD3), anti-Leu3
(CD4), anti-Leu2 (CD8), and anti-Leullb (CD16) antibodies
directly conjugated to fluorescein isothiocyanate (Becton
Dickinson Co., Mountain View, Calif.) were used to quan-
titate CD3+, CD4+, CD8+, and CD16+ cells in culture.
Briefly, 20 ,ul of antibody was added to 105 to 106 cells in 50
,ul and incubated for 60 min at 4°C. The cells were then
washed twice with cold RPMI 1640 and analyzed on a
fluorescence-activated cell sorter (FACS 440; Becton Dick-
inson Co.).
Cytotoxicity assays. B-LCL were infected with vaccinia
virus at an MOI of 10 PFU per cell and incubated for 12 to 14
h. Target cells (0.5 x 106) were then labeled with 0.5 mCi
(18.5 mBq) of Na251CrO4 (Dupont) in 0.2 ml of RPMI 1640
containing 10% FBS at 37°C for 1 h. The cells were then
washed three times and resuspended in RPMI 1640 contain-
ing 10% FBS. Cells (2 x 103/0.1 ml) were added in a 0.1-ml
volume to each well of a 96-well round bottom microtiter
plate (Costar). Various concentrations of effector cells in 0.1
ml of medium were added to each well to give the described
effector/target (EIT) cell ratios. After 5 h of incubation at
37°C, the supernatant was harvested from each well and
counted in a gamma counter. The assays were carried out in
triplicate wells, and percent specific lysis was calculated by
the formula 100 x [(mean experimental release - mean
spontaneous release)/(mean maximum release - mean spon-
taneous release)]. The spontaneous release was between 10
and 30%. Maximum release was determined by treatment of
labeled cells with detergent.
Antibody-complement depletion analysis. Anti-OKT3
(CD3), anti-OKT4 (CD4), and anti-OKT8 (CD8) antibodies
(Ortho Diagnostic Systems, Inc., Raritan, N.J.) and anti-
Leullb (CD16; Becton Dickinson Co.) antibodies were used
in antibody-complement depletion experiments. Vaccinia
virus-stimulated effector cells were resuspended in 0.5 ml of
RPMI 1640 supplemented with 2% FBS containing a 1:10
dilution of the antibody. Following 30 min of incubation at
4°C, the cells were washed with cold RPMI 1640 and
suspended in 0.6 ml to which 0.2 ml of rabbit complement
(Cedarlane Laboratories, Homby, Ontario, Canada) was
added. After 1 h of incubation at 37°C, the cells were washed
three times and used as effector cells in cytotoxicity assays.
Antibody blocking of cytotoxicity. W6/32 (Accurate Chem-
ical and Scientific Co., Westbury, N.Y.) and OKIa-1 (Ortho)
are monoclonal antibodies which recognize framework de-
terminants of HLA A, B, and C, and DR determinants,
respectively. A 50-p,u volume of antibody diluted 1:20 was
added to 50 pul of 51Cr-labeled target cells (104 cells per ml) in
96-well round-bottom plates for 30 min; this was followed by
addition of 100 pl of effector cells for incubation at 37°C for
5 h.
T-cell cloning by limiting dilution. PBMC from immune
donors were stimulated with vaccinia virus by infection of
10% of the cells at an MOI of 75 or 100 PFU per cell. After
7 days in culture, an aliquot of the stimulated cells was used
as effector cells in a CTL assay and the remaining cells were
restimulated. Autologous PBMC were gamma irradiated
(3,000 R), and 10% of the irradiated cells were infected with
vaccinia virus for use as stimulators. After infection with
vaccinia virus, the 10% infected, gamma-irradiated autolo-
gous PBMC and the 90% uninfected, gamma-irradiated
autologous feeder PBMC were combined and resuspended
to 106 cells per ml in RPMI 1640 containing 10% FBS, 10%
T-cell growth factor, and 10% heat-inactivated vaccinia
virus-immune human serum (source of vaccinia virus anti-
body) and added to the bulk cultures for restimulation.
Preliminary experiments revealed that addition of vaccinia
virus-immune serum resulted in improved viability of the
cultured cells, presumably by neutralizing residual infectious
vaccinia virus.
After 14 days in culture, the bulk effector cells were
diluted and placed in 96-well round-bottom plates at a
concentration of 1, 3, or 9 cells per well. Every 7 to 11 days,
the plates were restimulated with virus-infected, autologous,
gamma-irradiated PBMC. In some experiments, as an alter-
nate method of stimulation, the cells were stimulated by 0.1
,g of anti-CD3 monoclonal antibody 12F6 per ml, kindly
provided by Johnson Wong, and were placed on gamma-
irradiated allogeneic feeder cells in the medium described
above containing 25 U of recombinant human interleukin 2
(Collaborative Research, Inc., Bedford, Mass.) per ml. Once
weekly, half of the medium was removed and fresh medium
was added. After approximately four stimulations, the
clones were expanded in flat-bottom 48-well plates (Costar)
and tested for cytotoxic activity. For generation of clones
JC-FC4 and JC-FD7, CD8+ cells were preferentially sepa-
rated from bulk cultures by positive selection with anti-
CD8+ monoclonal antibodies conjugated to magnetic beads
(Becton Dickinson) and then seeded at 1 cells per well by
limiting dilution (29).
HLA typing. Donor JC, CB, CP, H12, 63390, and PG
B-LCL from the University of Massachusetts Medical Cen-
ter were HLA typed in the University of Massachusetts
Medical Center Tissue Typing Laboratory. GM3106 B-LCL
were obtained from the National Institute of General Medi-
cal Sciences Human Genetic Mutant Cell Repository, Cam-
den, N.J.
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TABLE 1. Proliferative responses of vaccinia virus-immune
donor PBMC after stimulation with live virus or virus-infected
stimulator cells
Expt Responder, stimulator MOI cpm SIa
1 PBMC" vaccinia virus 0.0064 5,225 6.0
PBMC, vaccinia virus 0.032 10,014 11.5
PBMC, vaccinia virus 0.16 15,121 17.3
PBMC, vaccinia virus 0.8 16,441 18.8
PBMC, vaccinia virus 4.0 14,326 16.4
PBMC, vaccinia virus 20 442 0.5
PBMC, vaccinia virus 100 61 0.0
PBMC, none (control) 874
2 PBMC', PBMC + virusd 0.1 1,144 1.3
PBMC, PBMC + virus 1.0 4,273 4.9
PBMC, PBMC + virus 10.0 10,488 12.0
PBMC, PBMC + virus 100 16,706 19.1
PBMC, none (control) 874
a The stimulation index (SI) was calculated by dividing the amount of
stimulation by the control (PBMC alone).
I PBMC taken from vaccinia virus-immune donor C were added at 2 x 105
cells per well in triplicate wells.
c Donor C PBMC were added at 1.8 x 101 cells per well in triplicate wells.
d PBMC (0.2 x 105) were infected with virus at the indicated MOI.
RESULTS
Proliferative responses of human immune PBMC after
stimulation with live virus in vitro. PBMC from immune
donors who had been revaccinated with vaccinia virus 2
months or 4 years earlier were stimulated in vitro with live
virus or an aliquot of virus-infected, autologous PBMC. In
addition, PBMC from a nonimmune donor and two cord
blood samples were also stimulated. The proliferative re-
sponses of the stimulated PBMC were determined by mea-
suring [3H]thymidine incorporation after 5 days of culture,
and the results are shown in Table 1. Stimulation of nonim-
mune PBMC with live vaccinia virus resulted in no detect-
able proliferation (data not shown). When infectious virus
was added directly to PBMC, maximum proliferation was
observed at an MOI of 0.8 (Table 1, experiment 1). As the
MOI increased, the proliferation decreased, owing to virus-
induced cell death. High levels of proliferation were also
observed when 10% of the PBMC were preinfected with
virus at an MOI of 100 and added to responder PBMC (Table
1, experiment 2). These results indicated that vaccinia virus-
specific T cells proliferate in vitro after stimulation with live
vaccinia virus.
Cytotoxic T-cell activity in bulk cultures stimulated by live
vaccinia virus. PBMC from the same immune donor were
stimulated in vitro with virus-infected PBMC, and a CTL
assay was performed on day 7 to determine the cytolytic
activity against autologous virus-infected target cells (Table
2, experiment 1). Vaccinia virus-infected B-LCL were lysed
to higher levels than uninfected B-LCL. Additional stimula-
tion of the cells was done on day 7, and the cells were tested
again for CTL activity on day 13 (Table 2, experiment 2). On
day 13, cells in the live-virus-stimulated cultures specifically
lysed vaccinia virus-infected targets. Although the cells in
the bulk cultures stimulated with live virus maintained
virus-specific killing on day 13, we were concerned that
eventually residual infectious virus would infect and destroy
the cells in culture. We decided, therefore, to supplement
the culture medium with anti-vaccinia virus antibodies by
replacing the 10% heat-inactivated human AB serum with
10% heat-inactivated human immune sera taken from donors
TABLE 2. Specific anti-vaccinia virus cytotoxicity of PBMC
restimulated in vitro
% Specific 51Cr release
Effector cells from target cells at E/TExpt (day) Target ratio of:
100:1 50:1 25:1
1 PBMC (7)a B-LCL 22.5 11.7
VACb 77.4 66.0
2 PBMC (13)C B-LCL 0.1 0.0
VACb 40.6 25.8
3 PBMC (10)d B-LCL 13.5 0.0
VAC" 73.9 39.3
Fibroblasts 19.8 11.0
VAC-fibroblasts 51.6 44.7
K562 71.1 49.4
a PBMC were taken from donor C at 4 years post revaccination with
vaccinia virus, stimulated in vitro with live-virus-infected cells, and assayed
on day 7.
b Autologous B-LCL infected with vaccinia virus.
c Same PBMC bulk culture assayed on day 13 (after stimulation on day 7).
d Same PBMC as used in experiment 1 but maintained in the presence of
anti-vaccinia virus antibody.
2 to 4 months post revaccination. These cultures were
maintained by stimulation with virus-infected autologous
PBMC and cultured in the presence of human immune serum
antibodies. On day 10 after stimulation, the virus-specific
CTL activity was high and appeared to be specific, with a
low level of lysis of uninfected B-LCL targets (Table 2,
experiment 3). Autologous fibroblasts were also included as
target cells to detect CD8+ CTL activity because fibroblasts
express class I but do not constitutively express class II
MHC antigens (16). Specific killing of the virus-infected
fibroblasts suggested that virus-specific CD8+ CTL were
present in this bulk culture.
Characterization of cytotoxic effector cells by using mono-
clonal antibodies. To determine the identities of the respond-
ing vaccinia virus-specific CTL in bulk culture, antibody and
complement depletion studies were carried out. PBMC
taken from three donors (A, B, and C) were stimulated in
vitro with virus-infected autologous PBMC and maintained
in the presence of a high titer of anti-vaccinia virus antibody.
The results of antibody-complement depletion of cells from
7-day bulk cultures on CTL activity are presented in Table 3,
experiments 1 and 2. The bulk-cultured cells were tested for
cytotoxic activity against autologous B-LCL; virus-infected,
autologous B-LCL (VAC); and natural killer (NK) cell-
sensitive tumor cell line K562. The cells generated from
donor A efficiently lysed VAC targets. Treatment with
anti-CD8 and complement decreased the lytic activity by
25.1%, and anti-CD16 and complement decreased lysis by
62.5%. Donor B's cells exhibited some nonspecific lysis of
B-LCL, and treatment with anti-CD16 and complement
inhibited the lysis of VAC targets by 32.6%. Treatment with
anti-CD4 and complement inhibited lysis of VAC targets by
67.4%, suggesting a dominant role for CD4+ CTL in this
culture. Taken together, these results suggest that 7 days
after stimulation in vitro, specific anti-vaccinia virus CTL
and CD16+ killer cells were activated in bulk cultures, and
these responses were heterogeneous and varied between
donors.
The same experiment was repeated on two cultures on day
31. Cells generated from donor C had been stimulated four
J. VIROL.
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TABLE 3. Characterization of bulk culture cytotoxic activity
% Specific 51Cr release from target
Donor (day), expt, treatment cells
B-LCL VACa K562
A (7)b 1
Complement 6.7 59.7 72.4
Anti-CD4+ complement 5.2 56.7 67.5
Anti-CD8+ complement 3.2 44.7 63.9
Anti-CD3+ complement 2.8 45.7 70.0
Anti-CD16+ complement 1.3 22.4C 24.2
B (7)d, 2
Complement 27.3 47.0 60.3
Anti-CD4+ complement 10.9 15.3 46.5
Anti-CD8+ complement 18.5 37.7 59.3
Anti-CD3+ complement 15.0 11.8 43.8
Anti-CD16+ complement 20.4 31.7 2L.1
C (31)e, 3
Complement -3.2 47.1 -1.8
Anti-CD4+ complement -4.2 47.3 -0.8
Anti-CD8+ complement -2.7 7.2 -6.8
Anti-CD3+ complement NDf ND ND
Anti-CD16+ complement -1.5 43.2 -3.8
A (31w, 4
Complement -5.1 18.3 4.7
Anti-CD4+ complement -5.8 14.8 3.2
Anti-CD8+ complement -7.6 0.0 2.3
Anti-CD3+ complement -5.4 16 0.0
Anti-CD16+ complement -7.8 11.6 2.4
a Autologous B-LCL infected with vaccinia virus.
b PBMC taken from donor A at 2 months post revaccination and stimulated
once in vitro with virus. E/T ratio, 60:1.
c Underlined values are those which were significantly decreased by
treatment.
d PBMC taken from donor B at 2 months post revaccination and stimulated
once in vitro with virus. E/T ratio, 50:1.
e Donor C bulk stimulated four times in vitro with virus. E/T ratio, 20:1.
f ND, not done.
g Donor A bulk stimulated four times in vitro (twice with virus and then
twice with anti-CD3). E:T ratio, 45:1.
times in vitro with virus-infected autologous PBMC, while
cells from donor A had been stimulated twice with virus-
infected cells and then stimulated twice with anti-CD3 mono-
clonal antibody. The results are shown in Table 3, experi-
ments 3 and 4. The lytic activity of the cells from donor C
was inhibited by 84.7% following treatment with anti-CD8
and complement. No other antibody had a significant effect
on lysis by cells in this culture. Similarly, donor A's cells lost
all killing activity after treatment with anti-CD8 and comple-
ment, and no other antibody had a significant effect on the
levels of lysis. Taken together, the results of antibody and
complement depletion on CTL activity indicate that stimu-
lation of donor immune PBMC in vitro with virus-infected,
autologous PBMC activated CD8+ memory CTL and the
levels of CD8+ CTL activity varied between donors.
Establishment of vaccinia virus-specific CD8+ CTL clones.
To demonstrate firmly that virus-specific CD8+ memory
CTL are generated as a result of vaccination with vaccinia
virus, we attempted to establish vaccinia virus-specific
T-cell lines. Initially, bulk cultures ofPBMC of donors A and
C were stimulated twice with virus-infected autologous
PBMC. The cells were then diluted and added to 96-well
plates at 1, 3, or 9 cells per well. The plates were alterna-
tively stimulated every 10 to 14 days with either virus-
TABLE 4. Effect of anti-HLA antibodies on cytotoxic activity of
vaccinia virus-specific CTL lines
% Specific 51Cr release from target cells
T-cell Phntpbline Phenotype VAC B-LCL + B-LCL + B-LCL
AC W6/32" OKIa-le
KT-E3 CD8+ 59.9 1.3f 30.0 -1.3
KT-C5 CD4+ 59.3 41.9 2.7 -0.1
JC-DC7 CD8+ 81.2 0.8 49.1 0.0
JC-DD6 CD4+ 82.5 72.1 14.9 -8.0
JC-FC4 CD8+ 54.9 -7.3 51.9 -4.3
JC-FD7 CD8+ 59.0 0.9 61.7 1.4
a Lines were used at an E-T ratio of 30:1.
b As determined by FACS analysis.
c Autologous B-LCL infected with virus.
d Anti-class I monoclonal antibody diluted 1:80.
e Anti-DR monoclonal antibody diluted 1:80.
f Underlined values are those which were significantly decreased by treat-
ment.
infected, autologous PBMC or monoclonal antibody to CD3.
When cell numbers were large enough in wells which
showed proliferation, the cells were transferred to 48-well
plates. Several T-cell lines were generated by using this
approach, and six representative lines, two from donor A
and four from donor C, will be described here.
Two clones, JC-FC4 and JC-FD7, derived from donor C
were generated from plates which had been seeded at one
cell per well. Overall 2% of the wells were positive for
growth when seeded at one cell per well, and cells from 50%
of the growing (or 1% of the total number of wells) killed
vaccinia virus-infected autologous target cells. Two addi-
tional lines, JC-DC7 and JC-DD6, also derived from donor
C, were generated from plates which had been seeded at
three cells per well. Overall, 34% of the wells were positive
for growth when seeded at three cells per well, and cells
from 30% of the growing wells (or 11% of the total number of
wells) killed vaccinia virus-infected, autologous target cells.
Two other lines, KT-E3 and KT-C5, which were derived
from donor A, were generated from wells which had been
seeded at nine cells per well. Overall, cells in 56% of these
wells grew and were transferred to 48-well plates. A total of
24% of these growing wells (or 14% of the total number of
wells) had cells which lysed vaccinia virus-infected target
cells.
Cytotoxic activity of T-cell lines. The MHC restriction of
lines JC-FC4, JC-FD7, JC-DC7, JC-DD6, KT-E3, and
KT-C5 was examined in antibody blocking studies. Each of
the lines killed a high level of VAC targets but did not kill
uninfected targets (Table 4). Killing of the VAC targets by
lines KT-E3 and JC-DC7 and clones JC-FC4 and JC-FD7
was inhibited by >98% by anti-class I monoclonal antibody
W6/32. In contrast, incubation of targets with OKIa-1, an
anti-HLA-DR monoclonal antibody, inhibited lysis by lines
KT-C5 and JC-DD6 by 95 and 82%, respectively.
Cell surface phenotypes of vaccinia virus-specific CTL lines.
In addition to the antibody blocking study described above,
lines JC-DC7 and KT-E3 and clones JC-FC4 and JC-FD7
were examined by FACS analysis, and their cell surface
phenotypes were CD3+, CD4-, CD8+, and CD16- (Table
4). FACS analysis was also carried out on lines JC-DD6 and
KT-C5, and their phenotypes were determined to be CD3+,
CD4+, CD8-, and CD16- (Table 4). Taken together, these
results indicate that CD8+, as well as CD4+, CTL are
present after revaccination with vaccinia virus and that these
VOL. 67, 1993
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CTL Line Target Shared HLA
Antigens
JC Autologous
CB B35, Cw4
JC-FC4 H12 Cw4
63390 A3,A24, Cw4
GM3106 B35, Cw4
PG A3
CP Cw6
iC
CB
JC-DC7 63390
GM3106
PG
CP
Autologous
B35, Cw4
Cw4
A3, A24, Cw4
B35, Cw4
A3
Cw6
0 10 20 30 40 50 60
% Specific Cytotoxicity
FIG. 1. HLA restriction patterns of vaccinia virus-specific CTL
line JC-DC7 and clone JC-FC4. CTL were tested for the ability to
lyse autologous and allogeneic, vaccinia virus-infected B-LCL tar-
gets matched at specific HLA class I loci, as indicated, with an E/T
ratio of 5:1 in a 5-h 5tCr release assay. The HLA class I serotypes of
the donors whose cells were used in these experiments were as
follows: donor JC, HLA A3, A24, B35, Cw4, Cw6; donor CB, HLA
A2, A23, B35, B44, Cw4; donor CP, HLA A2, A28, B51, Bw57,
Cw6; donor PG, HLA A2, A3, B7, B27, Cwl, Cw7; donor GM3106,
HLA Al, B35, Cw4; donor H12, HLA A2, A23, B44, B53, Bw4,
Cw4, Cw7; donor 63390, HLA A3, A24, B7, Bw62, Cw4, Cw7.
CTL are maintained as memory cells for at least 4 years post
revaccination.
Cytotoxic activity of CTL lines and clones against vaccinia
virus-infected allogeneic target cells. Vaccinia virus-specific
CTL line JC-DC7 and clone JC-FC4 were tested for cyto-
toxic activity against a panel of allogeneic B-LCL that
shared HLA class I antigens to analyze MHC class I
restriction. Preliminary experiments suggested that HLA
B35 was the restricting allele. Clones JC-DC7 and JC-FC4
lysed several vaccinia virus-infected, allogeneic target cells
that shared both the HLA B35 and Cw4 allels (Fig. 1 and
data not shown); however, allogeneic targets that shared
only Cw4 and not B35 were not lysed (Fig. 1). These results
strongly suggest that these two vaccinia virus-specific CTL
clones are restricted by HLA B35.
DISCUSSION
In this communication, we describe the proliferation of
human vaccinia virus-immune PBMC in response to live
vaccinia virus-infected cells and characterize the CD4+ and
CD8+ CTL activities of these cells in vitro. We also gener-
ated vaccinia virus-specific CD4+ and CD8+ CTL lines and
clones from two vaccinia virus-immune individuals. The
restricting allele for two of these CD8+ lines appears to be
HLA B35. This is the first demonstration of vaccinia virus-
specific CD8+ CTL in humans. Previously, attempts have
been made to identify and characterize CTL responses in
vaccinia virus-immune humans, and only CD4+ CTL re-
sponses were identified following stimulation with inacti-
vated vaccinia virus antigens (15). In this study, we used live
virus-infected cells to stimulate cultures in vitro to induce
proliferation of CD8+ CTL.
CTL which recognize virus-infected cells and kill them are
thought to be the principal effector cells during viral infec-
tion. The importance of CTL in the outcome of viral infec-
tions has been demonstrated in several experimental sys-
tems (3, 14). The best-defined CTL are CD8+, which
recognize viral antigens in association with MHC class I
molecules, which are distributed on all cells. The roles that
MHC class II-restricted CD4+ CTL play during viral infec-
tions are not well understood, but they may be important in
controlling infection in cells which express large amounts of
class II MHC antigens.
The importance of cell-mediated immune responses asso-
ciated with infection or immunization with vaccinia virus has
been established (6, 8, 23, 31). CTL responses following
infection with poxviruses have been documented in a num-
ber of species, including mice, rats, rabbits, and sheep (2, 7,
12, 16, 18, 31). However, CTL responses to vaccinia virus
have not been well characterized in nonhuman primates or in
humans (22, 26).
Specific anti-vaccinia virus CD4+ or CD8+ CTL responses
were not detected in studies performed with subhuman
primates (26) or with humans (11, 22). Early attempts by
Perrin et al. to detect CTL in the PBMC of vaccinia
virus-immune humans were unsuccessful (22). Vaccinia vi-
rus-specific cytotoxic activity was detected in PBMC by day
5 after vaccination, peaked by days 7 to 8, and subsided by
day 12. The researchers found only weak suggestions of
participation of classical CTL and concluded that cells
bearing Fc receptors and acting in the presence of specific
antibodies, not CTL, were primarily responsible for the lysis
of virus-infected target cells (22). Stitz et al. searched for
specific vaccinia virus CTL in rhesus monkeys that had been
immunized by intracutaneous or intravenous injection of 108
PFU of vaccinia virus (26). At 5 to 6 days postimmunization,
auxiliary lymph node cells, peripheral blood cells, and
spleen cells obtained by partial splenectomy were tested for
virus-specific cytotoxic activity in vitro. Cytotoxic activity
peaked at 5 to 7 days postinfection and was present in
T-cell-depleted but not in T-cell-enriched fractions. The
investigators concluded that NK-like, not HLA-restricted,
T-cell activity was generated in lymphoid organs of rhesus
monkeys after vaccinia virus infection (26). Recently, Gra-
ham et al. used UV-inactivated vaccinia virus-infected fibro-
blasts to stimulate immune PBMC in vitro to detect specific
CTL responses in revaccinated humans, and no convincing
vaccinia virus-specific CTL activity was observed (11). The
reasons for the inability to observe vaccinia virus-specific
cytotoxicity were not clear (11). In summary, vaccinia
virus-specific cytotoxic T-cell activity has been reported in
mice (2, 7, 16, 18), but several studies with subhuman
primates (26) and with humans (11, 22) have failed to detect
vaccinia virus-specific CTL responses.
Recently, Littaua et al. generated several HLA class
1I-restricted human CD4+ CTL clones by using UV-inacti-
vated vaccinia virus-pulsed PBMC to stimulate immune T
cells in vitro (15). This was the first demonstration of
vaccinia virus-specific CTL in humans; however, the ques-
tion of whether CD8+ CTL play any role in vaccinia virus
immunity in humans remained unanswered. Morrison et al.
reported that influenza virus-specific CD8+ CTL were acti-
vated when influenza virus-infected splenocytes were used
as stimulators in vitro, but stimulation with UV-inactivated
virus-pulsed splenocytes preferentially gave rise to CD4+
CTL (19). In addition, van Binnendijk et al. were able to
establish measles virus-specific human CD8+ class I-re-
stricted clones after repeated in vitro simulation of immune
T-cell cultures with measles virus-infected autologous
B-LCL, whereas immune cultures stimulated with UV-
inactivated measles virus-pulsed autologous cells preferen-
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tially generated CD4+ CTL clones (28). We therefore chose
to stimulate CD8+ CTL in vitro by using vaccinia virus-
infected autologous cells. This approach differs from previ-
ous attempts to demonstrate CTL in subhuman primates and
in humans without in vitro stimulation (22, 26). NK cell
activation is an early antiviral host response, and a modest
level of specific CTL activity may be masked by NK
activity. In vitro stimulation allows for proliferation of
antigen-specific CTL after the NK activity subsides. It is
possible that the failure of Graham et al. and Littania et al. to
demonstrate human vaccinia virus-specific CD8+ CTL was
due to the inactivated nature of the stimulating antigen in
their experimental systems (11, 15). We generated vaccinia
virus-specific CD8+ and CD4+ CTL lines from two donors,
one whose PBMC were obtained 2 months post revaccina-
tion and one whose PBMC were obtained 4 years post
revaccination. Apparently, the method of in vitro stimula-
tion used to generate T-cell lines from vaccinia virus-im-
mune PBMC is directly related to the phenotypes of the
responding T cells.
We have established that both CD4+ and CD8+ vaccinia
virus-specific CTL can be generated in humans as a result of
vaccination and that both cell types persist as memory cells.
We did not determine the precursor frequency of vaccinia
virus-specific T cells in this study; however, such informa-
tion may be useful in light of the recent report by Cooney et
al. in which a recombinant vaccinia virus which expresses
human immunodeficiency virus type 1 gpl60 was used to
vaccinate humans against human immunodeficiency virus
(4). In this study, individuals who had been immunized many
years earlier with vaccinia virus had reduced humoral and
cellular immune responses to the novel gpl60 expressed in
the recombinant vaccine compared with the responses of
vaccinia virus-naive individuals. Their results suggest that
injection of vaccinia virus-immune individual with a recom-
binant vaccinia virus activates specific anti-vaccinia virus
memory T cells and the virus-infected cells may be elimi-
nated before a sufficient immune response can be induced by
the novel antigen. The inability to generate an efficient
immune response to a novel antigen expressed in a recom-
binant vaccinia virus in vaccinia virus-immune persons is
likely to be a major obstacle in developing such recombinant
vaccines.
Recombinant vaccinia viruses have been successful in
generating specific CTL responses against novel antigens
expressed in a recombinant vaccinia virus in vaccinia virus-
naive subhuman primates (24, 30). In chimpanzees, CD4+
CTL with specificity for human immunodeficiency virus
envelope glycoproteins have been demonstrated after immu-
nization with a vaccinia virus recombinant expressing hu-
man immunodeficiency virus type 1 glycoproteins (30). Sim-
ian immunodeficiency virus gag-specific CD8+ CTL were
induced by immunization of rhesus monkeys with a vaccinia
virus-simian immunodeficiency virus recombinant (24).
These results, in addition to the results reported in this
communication, are encouraging and suggest that recombi-
nant vaccinia viruses have potential for vaccination pur-
poses. An improved understanding of vaccinia virus-induced
immune responses, including memory T-cell responses,
should be helpful in designing experimental recombinant
vaccinia viruses which contain novel, medically important
antigens.
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